>> Sommaire

Special Report
Bionetwork Banking on Sublingual Galenic Forms

http://www.bulletins-electroniques.com/actualites/59798.htm

Professor François Allaert is a rare find among academics. About twelve years ago, he created his first business, CEN Biotech, and then created another, CEN Nutriment, which was inaugurated last February. Meanwhile, after having set up the Medical Marketing Assessment of Health Claims (EMMAS) Chair at the Ecole Supérieure de Commerce de Dijon (Dijon graduate school of business where he teaches), Professor Allaert and Patrice Binay recently co-founded Bionetwork, a third business working on the design of very special sublingual galenic forms, in other words drugs that enter the bloodstream very rapidly after they are placed under the tongue. The first drug may be marketed within the next two or three years.

The Outcome of a Meeting Between a Fundamental Researcher and a Clinician

"Just think of the strides we'll make when sublingual galenic forms become available," said François Allaert at the outset. To begin with, let's take a look at pain. Now a drug takes 45 minutes to act on a migraine, but sublingual galenic forms will only take 5 minutes. This form of drug should also provide substantial comfort to different categories of patients, specifically cancer patients undergoing chemotherapy. As they are plagued by vomiting, they have trouble taking pills. This is also true for the elderly who have trouble swallowing. Several treatments now have to be injected into patients because otherwise they are destroyed by the enzymatic digestion process. Sublingual galenic forms would do away with the injections, and thus save money.

Set up about a year ago, Bionetwork is, "the outcome of a meeting between a fundamental researcher and a clinician, something that always produces original results," underscored the Dijon-based businessman/academic. For now, Bionetwork is producing standard galenic forms, but using fairly innovative processes, thus enabling the business to fund its research on sublingual galenic forms. After Patrice Binay filed the first patent, and they both filed another patent, the two founders of the new business plan to start the first human clinical trials over the next two months. "If the trials are conclusive, we can then plan to market our first drug in 2010-2012," he exclaimed. Obviously, Bionetwork's new process, which allows a drug to pass through the vessel wall and thus act very quickly, may be adapted to other drugs whose rapid action is critical. "We know that the drugs are effective. We are merely trying to make them more so," he explained.

A Business with all the Trumps

Bionetwork is an integral part of the approach that Professor François Allaert has been rolling out for more than twelve years. The clinical trials required for marketing the drugs developed by Bionetwork may be run at CEN Biotech, a business specializing in drug assessment. Bionetwork will also be devising food supplements that would be tested at CEN Nutriment, a company positioned on the assessment of nutrients, FOSHU, and standard foodstuffs. In this 'environment', small Bionetwork seems to have all the trumps to become a big company very fast, or at least a business that will make a difference on the markets targeted by its cofounders.

>> Suivant

<< Précédent



Version imprimable >>

Transmettre cette info par email >>

Recommander ce site à un collègue / ami >>



S'abonner au
eTech France >>



FAQ / foire aux questions >>

Conditions d'utilisation >>

Bionetwork - François Allaert - email: allaert@cenbiotech.com

Code brève
ADIT : 59798

ADIT - Jean-François Desessard - email: jfd@adit.fr

eTech France numéro 228 (2/07/2009) - ADIT / ADIT - http://www.bulletins-electroniques.com/actualites/59798.htm